Trial · NCT05556616
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) | Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 1 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 1 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 2 | Participants | ||
| Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) | Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg | 3 | Participants | ||
| Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 3 | Participants | ||
| Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 4 | Participants | ||
| Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 3 | Participants | ||
| Overall Response Rate (ORR) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 0 | 95% Confidence Interval 0.00 to 60.24 | percentage of participants | |
| Overall Response Rate (ORR) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 50 | 95% Confidence Interval 6.76 to 93.24 | percentage of participants | |
| Overall Response Rate (ORR) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 33.3 | 95% Confidence Interval 0.84 to 90.57 | percentage of participants | |
| Groups 2 and 3: Disease Control Rate (DCR) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 75.0 | 95% Confidence Interval 19.41 to 99.37 | percentage of participants | |
| Groups 2 and 3: Disease Control Rate (DCR) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 50.0 | 95% Confidence Interval 6.76 to 93.24 | percentage of participants | |
| Groups 2 and 3: Disease Control Rate (DCR) | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 66.7 | 95% Confidence Interval 9.43 to 99.16 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05556616/results